CPHI Frankfurt 2025: Achieving a Longer Release for Injectables
It is possible to achieve longer-acting injectable drug products that also do not require aseptic fill/finish thanks to a new advanced drug delivery system, reveals Mårten Rooth from Nanexa.
Administering injectables is generally considered to be burdensome for both healthcare professionals and patients, particularly when injections are required frequently and in a hospital/healthcare setting. Being able to reduce the frequency of dosing is a hot topic at the moment, especially within the type 2 diabetes and obesity markets, points out Mårten Rooth, CTO and Co-Founder of Nanexa AB — a drug development company that has designed an advanced system for long-acting injectables, PharmaShell.
“[PharmaShell’s] ability to work with virtually any GLP-1 [glucagon-like peptide-1] molecule, old ones as well as new ones, makes [Nanexa] competitive [in the market],” Rooth adds. “And, our technology is actually not limited to just once monthly depots, we can do much longer depots that that, and I think that could be very attractive when it comes to maintenance, treatment, and similar.”
The PharmaShell technology encases drug particles with a thin and dense inorganic coating, allowing for slow and continuous release into the bloodstream. With this drug delivery technology, it is possible to develop long depots, regardless of the half-life of the API while also protecting the API, Rooth remarks.
Additionally, as the API is protected with the coating, it is possible to use terminal sterilization on the drug product in its final package, removing the bottleneck of aseptic fill/finish and relieving the supply chain, Rooth continues. “Also, from the protective properties, we have seen that we can store peptides at room temperatures after sterilization, so, we don’t need the cold chain logistics,” he says.
Click the video above to view the full interview
About the Speaker
Mårten Rooth, PhD, is the Chief Technology Officer (CTO) and one of the Co-Founders of Nanexa AB — a drug development company that specializes in long-acting injectables.
Mårten’s academic experience is in chemistry, and he achieved his PhD in Materials Chemistry from Uppsala University in 2008. As part of his role at Nanexa, Mårten is involved in the development of the PharmaShell process and technology. PharmaShell is an advanced drug delivery system that is enabling a new generation of long-acting injectable to be administered in a comfortable, convenient, and tolerable way.
Music from #Uppbeat (free for Creators!):
https://uppbeat.io/t/richard-smithson/air
License code: QHDAN9DIKVMQW8EK